Search

Your search keyword '"Henry, Timothy"' showing total 2,978 results
Start Over Author "Henry, Timothy"
2,978 results on '"Henry, Timothy"'

1. Artificial Intelligence Can Improve Patient Management at the Time of a Pandemic: The Role of Voice Technology

Author

Jadczyk, Tomasz, Wojakowski, Wojciech, Tendera, Michal, Henry, Timothy D, Egnaczyk, Gregory, and Shreenivas, Satya

Subjects
Computer applications to medicine. Medical informatics, R858-859.7, Public aspects of medicine, RA1-1270
Abstract

Artificial intelligence–driven voice technology deployed on mobile phones and smart speakers has the potential to improve patient management and organizational workflow. Voice chatbots have been already implemented in health care–leveraging innovative telehealth solutions during the COVID-19 pandemic. They allow for automatic acute care triaging and chronic disease management, including remote monitoring, preventive care, patient intake, and referral assistance. This paper focuses on the current clinical needs and applications of artificial intelligence–driven voice chatbots to drive operational effectiveness and improve patient experience and outcomes.

Published
2021
Full Text
View/download PDF

2. Reassessing After-Hour Arrival Patterns and Outcomes in ST-Elevation Myocardial Infarction

Author

Langabeer, James, Alqusairi, Diaa, DelliFraine, Jami L., Fowler, Ray, King, Richard, Segrest, Wendy, and Henry, Timothy

Subjects
Medicine, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Abstract

Introduction: Differences in after-hours capability or performance of ST-elevation myocardial infarction (STEMI) centers has the potential to impact outcomes of patients presenting outside of regular hours. Methods: Using a prospective observational study, we analyzed all 1,247 non-transfer STEMI patients treated in 15 percutaneous coronary intervention (PCI) facilities in Dallas, Texas, during a 24-month period (2010-2012). Controlling for confounding factors through a variety of statistical techniques, we explored differences in door-to-balloon (D2B) and in-hospital mortality for those presenting on weekends vs. weekdays and business vs. after hours. Results: Patients who arrived at the hospital on weekends had larger D2B times compared to weekdays (75 vs. 65 minutes; KW=48.9; p16 minutes longer than those who arrived during business hours and a higher likelihood of mortality (OR 2.23, CI [1.15-4.32], p

Published
2015
Full Text
View/download PDF

6. Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out‐Of‐Pocket Expenses? Insights From ARTEMIS

Author

Rymer, Jennifer A, Kaltenbach, Lisa A, Peterson, Eric D, Cohen, David J, Fonarow, Gregg C, Choudhry, Niteesh K, Henry, Timothy D, Cannon, Christopher P, and Wang, Tracy Y

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cost Effectiveness Research, Heart Disease - Coronary Heart Disease, Cardiovascular, Heart Disease, Good Health and Well Being, Humans, Health Expenditures, Medication Adherence, Myocardial Infarction, Purinergic P2Y Receptor Antagonists, Treatment Outcome, copay, myocardial infarction, persistence, voucher, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Background Persistence to P2Y12 inhibitors after myocardial infarction (MI) remains low. Out-of-pocket cost is cited as a factor affecting medication compliance. We examined whether a copayment intervention affected 1-year persistence to P2Y12 inhibitors and clinical outcomes. Methods and Results In an analysis of ARTEMIS (Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study), patients with MI discharged on a P2Y12 inhibitor were stratified by baseline out-of-pocket medication burden: low ($0-$49 per month), intermediate ($50-$149 per month), and high (≥$150 per month). The impact of the voucher intervention on 1-year P2Y12 inhibitor persistence was examined using a logistic regression model with generalized estimating equations. We assessed the rates of major adverse cardiovascular events among the groups using a Kaplan-Meier estimator. Among 7351 MI-treated patients at 282 hospitals, 54.2% patients were in the low copay group, 32.0% in the middle copay group, and 13.8% in the high copay group. Patients in higher copay groups were more likely to have a history of prior MI, heart failure, and diabetes compared with the low copay group (all P

Published
2022

7. Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction

Author

d'Entremont, Marc-André, Lee, Shun Fu, Mian, Rajibul, Kedev, Sasko, Montalescot, Gilles, Cornel, Jan Hein, Stankovic, Goran, Moreno, Raul, Storey, Robert F., Henry, Timothy D., Skuriat, Elizabeth, Tyrwhitt, Jessica, Mehta, Shamir R., Devereaux, P.J., Eikelboom, John, Cairns, John A., Pitt, Bertram, and Jolly, Sanjit S.

Published
2024
Full Text
View/download PDF

9. The Path to a Match for Interventional Cardiology Fellowship: A Major SCAI Initiative

Author

Drachman, Douglas E., Addo, Tayo, Applegate, Robert J., Bartel, Robert C., Bortnick, Anna E., Dea, Francesca M., Helmy, Tarek, Henry, Timothy D., Khalif, Adnan, Kirtane, Ajay J., Levy, Michael, Lim, Michael J., Mahmud, Ehtisham, Mihatov, Nino, Parikh, Sahil A., Porter, Laura, Prasad, Abhiram, Rao, Sunil V., Razzouk, Louai, Shah, Samit, Shroff, Adhir, Tamis-Holland, Jacqueline E., Velagapudi, Poonam, Welt, Fredrick G., and Abbott, J. Dawn

Published
2024
Full Text
View/download PDF

10. Determining the Cause of Coronary Vasomotor Disorders in Patients With Ischemia and Nonobstructive Coronary Arteries: Design and Rationale of the DISCOVER INOCA Prospective, Multicenter Registry

Author

Shah, Samit M., Tremmel, Jennifer A., Henry, Timothy D., Smilowitz, Nathaniel R., Prasad, Megha, Kobayashi, Yuhei, Henry, Glen A., Samady, Habib, Samuels, Bruce A., Lerman, Amir, Moses, Jeffrey W., Pietras, Cody, Zhang, Zhiyuan, Tirziu, Daniela, Parise, Helen, Cristea, Ecaterina, Chamié, Daniel, Grubman, Daniel, Henrici, Kyna, Matmusaeva, Elzar, Latif, Nida, Cigarroa, Natasha, and Lansky, Alexandra J.

Published
2024
Full Text
View/download PDF

11. SYNERGY—Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry

Author

Jolly, Sanjit S., Lee, Shun Fu, Mian, Rajibul, Kedev, Sasko, Lavi, Shahar, Moreno, Raul, Montalescot, Gilles, Hillani, Ali, Henry, Timothy D., Asani, Valon, Storey, Robert F., Silvain, Johanne, Spratt, James C.S., d'Entremont, Marc-André, Stankovic, Goran, Zafirovska, Biljana, Natarajan, Madhu K., Sabate, Manel, Shreenivas, Satya, Pinilla-Echeverri, Natalia, Sheth, Tej, Altisent, Omar Abdul-Jawad, Ribas, Núria, Skuriat, Elizabeth, Tyrwhitt, Jessica, and Mehta, Shamir R.

Published
2024
Full Text
View/download PDF

12. Angiographic characteristics of patients with STEMI and COVID-19: Insights from NACMI registry

Author

Dehghani, Payam, Singh, Jyotpal, Mancini, G.B. John, Stanberry, Larissa, Bergstedt, Seth, Madan, Mina, Benziger, Catherine P., Ghasemzadeh, Nima, Bortnick, Anna, Kankaria, Rohan, Grines, Cindy L., Nayak, Keshav, Yildiz, Mehmet, Alraies, M Chadi, Bagai, Akshay, Patel, Rajan A.G., Amlani, Shy, Case, Brian C., Waksman, Ron, Shavadia, Jay S., Stone, Jay H., Acharya, Deepak, Javed, Nosheen, Bagur, Rodrigo, Garberich, Ross, Garcia, Santiago, and Henry, Timothy D.

Published
2024
Full Text
View/download PDF

13. Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial

Author

Nakamura, Kenta, Henry, Timothy D., Traverse, Jay H., Latter, David A., Mokadam, Nahush A., Answini, Geoffrey A., Williams, Adam R., Sun, Benjamin C., Burke, Christopher R., Bakaeen, Faisal G., DiCarli, Marcelo F., Chaitman, Bernard R., Peterson, Mark W., Byrnes, Dawn G., Ohman, E. Magnus, Pepine, Carl J., Crystal, Ronald G., Rosengart, Todd K., Kowalewski, Elaine, Koch, Gary G., Dittrich, Howard C., and Povsic, Thomas J.

Published
2024
Full Text
View/download PDF

16. When and how CNNs generalize to out-of-distribution category-viewpoint combinations

Author

Madan, Spandan, Henry, Timothy, Dozier, Jamell, Ho, Helen, Bhandari, Nishchal, Sasaki, Tomotake, Durand, Frédo, Pfister, Hanspeter, and Boix, Xavier

Subjects
Computer Science - Computer Vision and Pattern Recognition, Computer Science - Machine Learning
Abstract

Object recognition and viewpoint estimation lie at the heart of visual understanding. Recent works suggest that convolutional neural networks (CNNs) fail to generalize to out-of-distribution (OOD) category-viewpoint combinations, ie. combinations not seen during training. In this paper, we investigate when and how such OOD generalization may be possible by evaluating CNNs trained to classify both object category and 3D viewpoint on OOD combinations, and identifying the neural mechanisms that facilitate such OOD generalization. We show that increasing the number of in-distribution combinations (ie. data diversity) substantially improves generalization to OOD combinations, even with the same amount of training data. We compare learning category and viewpoint in separate and shared network architectures, and observe starkly different trends on in-distribution and OOD combinations, ie. while shared networks are helpful in-distribution, separate networks significantly outperform shared ones at OOD combinations. Finally, we demonstrate that such OOD generalization is facilitated by the neural mechanism of specialization, ie. the emergence of two types of neurons -- neurons selective to category and invariant to viewpoint, and vice versa.

Published
2020

18. Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial

Author

Ostovaneh, Mohammad R, Makkar, Raj R, Ambale-Venkatesh, Bharath, Ascheim, Deborah, Chakravarty, Tarun, Henry, Timothy D, Kowalchuk, Glen, Aguirre, Frank V, Kereiakes, Dean J, Povsic, Thomas J, Schatz, Richard, Traverse, Jay H, Pogoda, Janice, Smith, Rachel D, Marbán, Linda, Marbán, Eduardo, and Lima, Joao AC

Subjects
Heart Disease, Clinical Trials and Supportive Activities, Cardiovascular, Clinical Research, Heart Disease - Coronary Heart Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Cine, Male, Middle Aged, Myocardial Infarction, Myocardium, Myocytes, Cardiac, Retrospective Studies, Stem Cell Transplantation, Stroke Volume, Transplantation, Autologous, Ventricular Dysfunction, Left, Ventricular Function, Left, MRI, coronary artery disease, epidemiology
Abstract

Most cell therapy trials failed to show an improvement in global left ventricular (LV) function measures after myocardial infarction (MI). Myocardial segments are heterogeneously impacted by MI. Global LV function indices are not able to detect the small treatment effects on segmental myocardial function which may have prognostic implications for cardiac events. We aimed to test the efficacy of allogeneic cardiosphere-derived cells (CDCs) for improving regional myocardial function and contractility. In this exploratory analysis of a randomised clinical trial, 142 patients with post-MI with LVEF

Published
2021

20. A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial

Author

Bolli, Roberto, Mitrani, Raul D, Hare, Joshua M, Pepine, Carl J, Perin, Emerson C, Willerson, James T, Traverse, Jay H, Henry, Timothy D, Yang, Phillip C, Murphy, Michael P, March, Keith L, Schulman, Ivonne H, Ikram, Sohail, Lee, David P, O'Brien, Connor, Lima, Joao A, Ostovaneh, Mohammad R, Ambale‐Venkatesh, Bharath, Lewis, Gregory, Khan, Aisha, Bacallao, Ketty, Valasaki, Krystalenia, Longsomboon, Bangon, Gee, Adrian P, Richman, Sara, Taylor, Doris A, Lai, Dejian, Sayre, Shelly L, Bettencourt, Judy, Vojvodic, Rachel W, Cohen, Michelle L, Simpson, Lara, Aguilar, David, Loghin, Catalin, Moyé, Lem, Ebert, Ray F, Davis, Barry R, Simari, Robert D, and Network, for the Cardiovascular Cell Therapy Research

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cardiovascular, Clinical Trials and Supportive Activities, Rehabilitation, Stem Cell Research, Clinical Research, Stem Cell Research - Nonembryonic - Human, Heart Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Heart Failure, Humans, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells, Minnesota, Quality of Life, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Cell-based therapy, Clinical trial, Heart failure, Cardiovascular Cell Therapy Research Network, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

AimsCONCERT-HF is an NHLBI-sponsored, double-blind, placebo-controlled, Phase II trial designed to determine whether treatment with autologous bone marrow-derived mesenchymal stromal cells (MSCs) and c-kit positive cardiac cells (CPCs), given alone or in combination, is feasible, safe, and beneficial in patients with heart failure (HF) caused by ischaemic cardiomyopathy.Methods and resultsPatients were randomized (1:1:1:1) to transendocardial injection of MSCs combined with CPCs, MSCs alone, CPCs alone, or placebo, and followed for 12 months. Seven centres enrolled 125 participants with left ventricular ejection fraction of 28.6 ± 6.1% and scar size 19.4 ± 5.8%, in New York Heart Association class II or III. The proportion of major adverse cardiac events (MACE) was significantly decreased by CPCs alone (-22% vs. placebo, P = 0.043). Quality of life (Minnesota Living with Heart Failure Questionnaire score) was significantly improved by MSCs alone (P = 0.050) and MSCs + CPCs (P = 0.023) vs. placebo. Left ventricular ejection fraction, left ventricular volumes, scar size, 6-min walking distance, and peak oxygen consumption did not differ significantly among groups.ConclusionsThis is the first multicentre trial assessing CPCs and a combination of two cell types from different tissues in HF patients. The results show that treatment is safe and feasible. Even with maximal guideline-directed therapy, both CPCs and MSCs were associated with improved clinical outcomes (MACE and quality of life, respectively) in ischaemic HF without affecting left ventricular function or structure, suggesting possible systemic or paracrine cellular mechanisms. Combining MSCs with CPCs was associated with improvement in both these outcomes. These results suggest potential important beneficial effects of CPCs and MSCs and support further investigation in HF patients.

Published
2021

22. Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients The CCTRN SENECA Trial

Author

Bolli, Roberto, Perin, Emerson C, Willerson, James T, Yang, Phillip C, Traverse, Jay H, Henry, Timothy D, Pepine, Carl J, Mitrani, Raul D, Hare, Joshua M, Murphy, Michael P, March, Keith L, Ikram, Sohail, Lee, David P, O’Brien, Connor, Durand, Jean-Bernard, Miller, Kathy, Lima, Joao A, Ostovaneh, Mohammad R, Ambale-Venkatesh, Bharath, Gee, Adrian P, Richman, Sara, Taylor, Doris A, Sayre, Shelly L, Bettencourt, Judy, Vojvodic, Rachel W, Cohen, Michelle L, Simpson, Lara M, Lai, Dejian, Aguilar, David, Loghin, Catalin, Moyé, Lem, Ebert, Ray F, Davis, Barry R, Simari, Robert D, and Network, Cardiovascular Cell Therapy Research

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cardiovascular, Clinical Research, Cancer, Heart Disease, Stem Cell Research, Clinical Trials and Supportive Activities, cardiac repair, cardiooncology, chemotherapy, heart failure, stem cells, Cardiovascular Cell Therapy Research Network, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

BackgroundAnthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor prognosis, disproportionately affecting women and young adults. Administration of allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) is a promising approach to heart failure (HF) treatment.ObjectivesSENECA (Stem Cell Injection in Cancer Survivors) was a phase 1 study of allo-MSCs in AIC.MethodsCancer survivors with chronic AIC (mean age 56.6 years; 68% women; NT-proBNP 1,426 pg/ml; 6 enrolled in an open-label, lead-in phase and 31 subjects randomized 1:1) received 1 × 108 allo-MSCs or vehicle transendocardially. Primary objectives were safety and feasibility. Secondary efficacy measures included cardiac function and structure measured by cardiac magnetic resonance imaging (CMR), functional capacity, quality of life (Minnesota Living with Heart Failure Questionnaire), and biomarkers.ResultsA total of 97% of subjects underwent successful study product injections; all allo-MSC-assigned subjects received the target dose of cells. Follow-up visits were well-attended (92%) with successful collection of endpoints in 94% at the 1-year visit. Although 58% of subjects had non-CMR compatible devices, CMR endpoints were successfully collected in 84% of subjects imaged at 1 year. No new tumors were reported. There were no significant differences between allo-MSC and vehicle groups with regard to clinical outcomes. Secondary measures included 6-min walk test (p = 0.056) and Minnesota Living with Heart Failure Questionnaire score (p = 0.048), which tended to favor the allo-MSC group.ConclusionsIn this first-in-human study of cell therapy in patients with AIC, transendocardial administration of allo-MSCs appears safe and feasible, and CMR was successfully performed in the majority of the HF patients with devices. This study lays the groundwork for phase 2 trials aimed at assessing efficacy of cell therapy in patients with AIC.

Published
2020

24. Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs

Author

Doll, Jacob A, Kaltenbach, Lisa A, Anstrom, Kevin J, Cannon, Christopher P, Henry, Timothy D, Fonarow, Gregg C, Choudhry, Niteesh K, Fonseca, Eileen, Bhalla, Narinder, Eudicone, James M, Peterson, Eric D, and Wang, Tracy Y

Subjects
Cardiovascular, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Aged, Cost-Benefit Analysis, Deductibles and Coinsurance, Drug Costs, Female, Health Expenditures, Humans, Male, Medication Adherence, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists, Quality Improvement, Quality Indicators, Health Care, Time Factors, Treatment Outcome, United States, medication adherence, myocardial infarction, quality improvement, Cardiorespiratory Medicine and Haematology
Abstract

Background Hospitals commonly provide a short-term supply of free P2Y12 inhibitors at discharge after myocardial infarction, but it is unclear if these programs improve medication persistence and outcomes. The ARTEMIS (Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study) trial randomized hospitals to usual care versus waived P2Y12 inhibitor copayment costs for 1-year post-myocardial infarction. Whether the impact of this intervention differed between hospitals with and without pre-existing medication assistance programs is unknown. Methods and Results In this post hoc analysis of the ARTEMIS trial, we examined the associations of pre-study free medication programs and the randomized copayment voucher intervention with P2Y12 inhibitor persistence (measured by pharmacy fills and patient report) and major adverse cardiovascular events using logistic regression models including a propensity score. Among 262 hospitals, 129 (49%) offered pre-study free medication assistance. One-year P2Y12 inhibitor persistence and major adverse cardiovascular events risks were similar between patients treated at hospitals with and without free medication programs (adjusted odds ratio 0.93, 95% CI, 0.82-1.05 and hazard ratio 0.92, 95% CI, 0.80-1.07, respectively). The randomized copayment voucher intervention improved persistence, assessed by pharmacy fills, in both hospitals with (53.6% versus 44.0%, adjusted odds ratio 1.45, 95% CI, 1.20-1.75) and without (59.0% versus 48.3%, adjusted odds ratio 1.46, 95% CI, 1.25-1.70) free medication programs (Pinteraction=0.71). Differences in patient-reported persistence were not significant after adjustment. Conclusions While hospitals commonly report the ability to provide free short-term P2Y12 inhibitors, we did not find association of this with medication persistence or major adverse cardiovascular events among patients with insurance coverage for prescription medication enrolled in the ARTEMIS trial. An intervention that provided copayment assistance vouchers for 1 year was successful in improving medication persistence in hospitals with and without pre-existing short-term medication programs. Registration URL: https://www.clini​caltr​ials.gov/. Unique identifier: NCT02406677.

Published
2020

34. Mechanical Circulatory Support in Patients With COVID-19 Presenting With Myocardial Infarction

Author

Guddeti, Raviteja R., Sanina, Cristina, Jauhar, Rajiv, Henry, Timothy D., Dehghani, Payam, Garberich, Ross, Schmidt, Christian W., Nayak, Keshav R., Shavadia, Jay S., Bagai, Akshay, Alraies, Chadi, Mehra, Aditya, Bagur, Rodrigo, Grines, Cindy, Singh, Avneet, Patel, Rajan A.G., Htun, Wah Wah, Ghasemzadeh, Nima, Davidson, Laura, Acharya, Deepak, Kabour, Ameer, Hafiz, Abdul Moiz, Amlani, Shy, Wasserman, Hal S., Smith, Timothy, Kapur, Navin K., and Garcia, Santiago

Published
2023
Full Text
View/download PDF

38. EXACT Trial: Results of the Phase 1 Dose-Escalation Study

Author

Povsic, Thomas J., Henry, Timothy D., Traverse, Jay H., Anderson, R. David, Answini, Geoffrey A., Sun, Benjamin C., Arnaoutakis, George J., Boudoulas, Konstantinos D., Williams, Adam R., Dittrich, Howard C., Tarka, Elizabeth A., Latter, David A., Ohman, E. Magnus, Peterson, Mark W., Byrnes, Dawn, Pepine, Carl J., DiCarli, Marcelo F., Crystal, Ronald G., Rosengart, Todd K., and Mokadam, Nahush A.

Published
2023
Full Text
View/download PDF

39. Position Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock

Author

Damluji, Abdulla A., Tehrani, Behnam, Sinha, Shashank S., Samsky, Marc D., Henry, Timothy D., Thiele, Holger, West, Nick E.J., Senatore, Fortunato F., Truesdell, Alexander G., Dangas, George D., Smilowitz, Nathaniel R., Amin, Amit P., deVore, Adam D., Moazami, Nader, Cigarroa, Joaquin E., Rao, Sunil V., Krucoff, Mitchell W., Morrow, David A., and Gilchrist, Ian C.

Published
2022
Full Text
View/download PDF

40. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index

Author

Kunadian, Vijay, Baber, Usman, Pivato, Carlo A., Cao, Davide, Dangas, George, Sartori, Samantha, Zhang, Zhongjie, Angiolillo, Dominick J., Briguori, Carlo, Cohen, David J., Collier, Timothy, Dudek, Dariusz, Gibson, Michael, Gil, Robert, Huber, Kurt, Kaul, Upendra, Kornowski, Ran, Krucoff, Mitchell W., Dehghani, Payam, Mehta, Shamir, Moliterno, David J., Ohman, E. Magnus, Escaned, Javier, Sardella, Gennaro, Sharma, Samin K., Shlofmitz, Richard, Weisz, Giora, Witzenbichler, Bernhard, Džavík, Vladimír, Gurbel, Paul, Hamm, Christian W., Henry, Timothy, Kastrati, Adnan, Marx, Steven O., Oldroyd, Keith, Steg, P. Gabriel, Pocock, Stuart, and Mehran, Roxana

Published
2022
Full Text
View/download PDF

43. North American COVID-19 Myocardial Infarction (NACMI) Risk Score for Prediction of In-Hospital Mortality

Author

Dehghani, Payam, Schmidt, Christian W., Garcia, Santiago, Okeson, Brynn, Grines, Cindy L., Singh, Avneet, Patel, Rajan A.G., Wiley, Jose, Htun, Wah Wah, Nayak, Keshav R., Alraies, M. Chadi, Ghasemzadeh, Nima, Davidson, Laura J., Acharya, Deepak, Stone, Jay, Alyousef, Tareq, Case, Brian C., Dai, Xuming, Hafiz, Abdul Moiz, Madan, Mina, Jaffer, Faoruc A., Shavadia, Jay S., Garberich, Ross, Bagai, Akshay, Singh, Jyotpal, Aronow, Herbert D., Mercado, Nestor, and Henry, Timothy D.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results